{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:50:28Z","timestamp":1790736628311,"version":"4.1.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Ultrasonographic measurement of fetal nuchal translucency is used in prenatal screening for trisomies 21 and 18 and other conditions. A cutoff of 3.5 mm or greater is commonly used to offer follow-up investigations, such as prenatal cell-free DNA (cfDNA) screening or cytogenetic testing. Recent studies showed a possible association with chromosomal anomalies for levels less than 3.5 mm, but extant evidence has limitations.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between different nuchal translucency measurements and cytogenetic outcomes on a population level.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based retrospective cohort study used data from the Better Outcomes Registry &amp;amp; Network, the perinatal registry for Ontario, Canada. All singleton pregnancies with an estimated date of delivery from September 1, 2016, to March 31, 2021, were included. Data were analyzed from March 17 to August 14, 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Nuchal translucency measurements were identified through multiple-marker screening results.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Chromosomal anomalies were identified through all Ontario laboratory-generated prenatal and postnatal cytogenetic tests. Cytogenetic testing results, supplemented with information from cfDNA screening and clinical examination at birth, were used to identify pregnancies without chromosomal anomalies. Multivariable modified Poisson regression with robust variance estimation and adjustment for gestational age was used to compare cytogenetic outcomes for pregnancies with varying nuchal translucency measurement categories and a reference group with nuchal translucency less than 2.0 mm.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 414 268 pregnancies included in the study (mean [SD] maternal age at estimated delivery date, 31.5 [4.7] years), 359\u202f807 (86.9%) had a nuchal translucency less than 2.0 mm; the prevalence of chromosomal anomalies in this group was 0.5%. An increased risk of chromosomal anomalies was associated with increasing nuchal translucency measurements, with an adjusted risk ratio (ARR) of 20.33 (95% CI, 17.58-23.52) and adjusted risk difference (ARD) of 9.94% (95% CI, 8.49%-11.39%) for pregnancies with measurements of 3.0 to less than 3.5 mm. The ARR was 4.97 (95% CI, 3.45-7.17) and the ARD was 1.40% (95% CI, 0.77%-2.04%) when restricted to chromosomal anomalies beyond the commonly screened aneuploidies (excluding trisomies 21, 18, and 13 and sex chromosome aneuploidies).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of 414 268 singleton pregnancies, those with nuchal translucency measurements less than 2.0 mm were at the lowest risk of chromosomal anomalies. Risk increased with increasing measurements, including measurements less than 3.5 mm and anomalies not routinely screened by many prenatal genetic screening programs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.3689","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:22:45Z","timestamp":1711452165000},"page":"e243689","source":"Crossref","is-referenced-by-count":20,"title":["Ultrasonographic Fetal Nuchal Translucency Measurements and Cytogenetic Outcomes"],"prefix":"10.1001","volume":"7","author":[{"given":"Kara","family":"Bellai-Dussault","sequence":"first","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Prenatal Screening Ontario for Better Outcomes Registry & Network Ontario, Ottawa, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario Research Institute, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley D.","family":"Dougan","sequence":"additional","affiliation":[{"name":"Prenatal Screening Ontario for Better Outcomes Registry & Network Ontario, Ottawa, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario Research Institute, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshayne B.","family":"Fell","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario Research Institute, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Little","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Meng","sequence":"additional","affiliation":[{"name":"Prenatal Screening Ontario for Better Outcomes Registry & Network Ontario, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Okun","sequence":"additional","affiliation":[{"name":"Prenatal Screening Ontario for Better Outcomes Registry & Network Ontario, Ottawa, Canada"},{"name":"DAN Women & Babies Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Walker","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Prenatal Screening Ontario for Better Outcomes Registry & Network Ontario, Ottawa, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario Research Institute, Ottawa, Canada"},{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Armour","sequence":"additional","affiliation":[{"name":"Prenatal Screening Ontario for Better Outcomes Registry & Network Ontario, Ottawa, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario Research Institute, Ottawa, Canada"},{"name":"Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth K.","family":"Potter","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"3","key":"zoi240159r2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.siny.2013.11.013","article-title":"A historical and practical review of first trimester aneuploidy screening.","volume":"19","author":"Russo","year":"2014","journal-title":"Semin Fetal Neonatal Med"},{"issue":"6831","key":"zoi240159r3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/bmj.304.6831.867","article-title":"Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.","volume":"304","author":"Nicolaides","year":"1992","journal-title":"BMJ"},{"issue":"9","key":"zoi240159r4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jogc.2017.01.032","article-title":"No. 348-Joint SOGC-CCMG Guideline: update on prenatal screening for fetal aneuploidy, fetal anomalies, and adverse pregnancy outcomes.","volume":"39","author":"Audibert","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"zoi240159r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0969141315595826","article-title":"Pregnancy outcome for fetuses with increased nuchal translucency but normal karyotype.","volume":"23","author":"Lithner","year":"2016","journal-title":"J Med Screen"},{"issue":"2","key":"zoi240159r7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/pd.v36.2","article-title":"The performance of an intermediate 16th-week ultrasound scan for the follow-up of euploid fetuses with increased nuchal translucency.","volume":"36","author":"Le Lous","year":"2016","journal-title":"Prenat Diagn"},{"issue":"4","key":"zoi240159r8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/pd.v37.4","article-title":"Chorionic villus sampling in the cell-free DNA aneuploidy screening era: careful selection criteria can maximise the clinical utility of screening and invasive testing.","volume":"37","author":"Kane","year":"2017","journal-title":"Prenat Diagn"},{"issue":"4","key":"zoi240159r9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ajog.2004.12.093","article-title":"Increased nuchal translucency with normal karyotype.","volume":"192","author":"Souka","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"zoi240159r10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/pd.v40.2","article-title":"Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?","volume":"40","author":"Bardi","year":"2020","journal-title":"Prenat Diagn"},{"issue":"1","key":"zoi240159r11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/uog.v30:1","article-title":"Increased nuchal translucency thickness and normal karyotype: time for parental reassurance.","volume":"30","author":"Bilardo","year":"2007","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"3","key":"zoi240159r12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/medsci7030040","article-title":"Chromosomal microarray analysis versus karyotyping in fetuses with increased nuchal translucency.","volume":"7","author":"Cicatiello","year":"2019","journal-title":"Med Sci (Basel)"},{"issue":"2","key":"zoi240159r13","first-page":"174","article-title":"Contribution of array CGH in the management of fetal nuchal translucency.","volume":"48","author":"Beal","year":"2020","journal-title":"Gynecol Obstet Fertil Senol"},{"issue":"18","key":"zoi240159r14","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1080\/14767058.2019.1568405","article-title":"Abnormal nuchal translucency: residual risk with normal cell-free DNA screening.","volume":"33","author":"Grossman","year":"2020","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"6","key":"zoi240159r15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/uog.2015.46.issue-6","article-title":"Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: a systematic review and meta-analysis.","volume":"46","author":"Grande","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"8","key":"zoi240159r16","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.v7.8","article-title":"Clinical application of chromosomal microarray analysis in fetuses with increased nuchal translucency and normal karyotype.","volume":"7","author":"Su","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"zoi240159r17","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6504159","article-title":"Prenatal diagnostic value of chromosomal microarray in fetuses with nuchal translucency greater than 2.5?mm.","volume":"2019","author":"Zhang","year":"2019","journal-title":"Biomed Res Int"},{"issue":"6","key":"zoi240159r18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/uog.2018.52.issue-6","article-title":"Diagnostic yield of chromosomal microarray analysis in fetuses with isolated increased nuchal translucency: a French multicenter study.","volume":"52","author":"Egloff","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"zoi240159r19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/AOG.0000000000004195","article-title":"Risk of clinically significant chromosomal microarray analysis findings in fetuses with nuchal translucency from 3.0 mm through 3.4 mm.","volume":"137","author":"Sagi-Dain","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"3","key":"zoi240159r20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/uog.2017.50.issue-3","article-title":"Cut-off value of nuchal translucency as indication for chromosomal microarray analysis.","volume":"50","author":"Maya","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"6","key":"zoi240159r21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/pd.5051","article-title":"Non-invasive prenatal screening versus prenatal diagnosis by array comparative genomic hybridization: a comparative retrospective study.","volume":"37","author":"Sotiriadis","year":"2017","journal-title":"Prenat Diagn"},{"issue":"6","key":"zoi240159r22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/aogs.v99.6","article-title":"Nuchal translucency of 3.0-3.4 mm an indication for NIPT or microarray? cohort analysis and literature review.","volume":"99","author":"Petersen","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"10","key":"zoi240159r23","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1080\/14767058.2019.1569622","article-title":"Application of chromosomal microarray in fetuses with increased nuchal translucency.","volume":"33","author":"Zhao","year":"2020","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"5","key":"zoi240159r24","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/ije\/dyab033","article-title":"Data Resource Profile: Better Outcomes Registry & Network (BORN) Ontario.","volume":"50","author":"Murphy","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"2","key":"zoi240159r26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/pd.v40.2","article-title":"A 2-year review of publicly funded cell-free DNA screening in Ontario: utilization and adherence to funding criteria.","volume":"40","author":"Bellai-Dussault","year":"2020","journal-title":"Prenat Diagn"},{"issue":"30","key":"zoi240159r28","doi-asserted-by":"publisher","first-page":"E1156","DOI":"10.1503\/cmaj.202456","article-title":"Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada.","volume":"193","author":"Dougan","year":"2021","journal-title":"CMAJ"},{"issue":"11","key":"zoi240159r29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2020.12698","article-title":"Estimating risk ratios and risk differences: alternatives to odds ratios.","volume":"324","author":"Holmberg","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"zoi240159r30","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/aje\/kwr183","article-title":"Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data.","volume":"174","author":"Yelland","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"4","key":"zoi240159r31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/01443615.2017.1391755","article-title":"What would be missed in the first trimester if nuchal translucency measurement is replaced by cell free DNA foetal aneuploidy screening?","volume":"38","author":"Huang","year":"2018","journal-title":"J Obstet Gynaecol"},{"issue":"6","key":"zoi240159r32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/aogs.v99.6","article-title":"Current use of noninvasive prenatal testing in Europe, Australia and the USA: a graphical presentation.","volume":"99","author":"Gadsb\u00f8ll","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"zoi240159r33","doi-asserted-by":"publisher","first-page":"8437","DOI":"10.2147\/IJGM.S330960","article-title":"Different cutoff values for increased nuchal translucency in first-trimester screening to predict fetal chromosomal abnormalities.","volume":"14","author":"Su","year":"2021","journal-title":"Int J Gen Med"},{"key":"zoi240159r34","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/482832","article-title":"Analysis of quality of nuchal translucency measurements: its role in prenatal diagnosis.","volume":"2012","author":"Gabriel","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"2","key":"zoi240159r35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/uog.v34:2","article-title":"Quality of nuchal translucency measurements in the Netherlands: a quantitative analysis.","volume":"34","author":"Koster","year":"2009","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"5","key":"zoi240159r36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/uog.v58.5","article-title":"United States\u2019 experience in nuchal translucency measurement: variation according to provider characteristics in over five million ultrasound examinations.","volume":"58","author":"Thornburg","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"2","key":"zoi240159r37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/uog.2015.45.issue-2","article-title":"Nuchal Translucency Quality Review (NTQR) program: first one and half million results.","volume":"45","author":"Cuckle","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"zoi240159r38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/AOG.0b013e3181f23ae3","article-title":"Undermeasurement of nuchal translucencies: implications for screening.","volume":"116","author":"Evans","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"6","key":"zoi240159r39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000106342","article-title":"Nuchal translucency measurements for first-trimester screening: the \u201cprice\u201d of inaccuracy.","volume":"22","author":"Evans","year":"2007","journal-title":"Fetal Diagn Ther"},{"issue":"3","key":"zoi240159r40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/uog.v55.3","article-title":"Microarray and RASopathy-disorder testing in fetuses with increased nuchal translucency.","volume":"55","author":"Sinajon","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"zoi240159r41","doi-asserted-by":"publisher","first-page":"E436","DOI":"10.9778\/cmajo.20180046","article-title":"Trends in the use of prenatal testing services for fetal aneuploidy in Ontario: a descriptive study.","volume":"6","author":"Huang","year":"2018","journal-title":"CMAJ Open"},{"key":"zoi240159r1","unstructured":"Fetal Medicine Foundation. FMF certification nuchal translucency scan. Accessed January 24, 2022. https:\/\/fetalmedicine.org\/fmf-certification-2\/nuchal-translucency-scan"},{"key":"zoi240159r6","unstructured":"Nicolaides? KH. The 11-13+6 weeks scan. Fetal Medicine Foundation. 2004. Accessed May 30, 2023. https:\/\/fetalmedicine.org\/fmf\/FMF-English.pdf"},{"key":"zoi240159r25","unstructured":"BORN Ontario. Program report: prenatal screening Ontario, 2019-2020. December 2021. Accessed July 19, 2023. https:\/\/www.bornontario.ca\/en\/pso\/resources\/Remediated-PDFs-2020\/PSO-Program-Report---FINAL-Dec-8-2021.pdf"},{"key":"zoi240159r27","unstructured":"Prenatal Screening Ontario. About the Nuchal Translucency Quality Assurance (NTQA) program. Accessed May 30, 2023. https:\/\/www.prenatalscreeningontario.ca\/en\/pso\/for-sonographers\/nt-quality-assurance.aspx"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2816745\/bellaidussault_2024_oi_240159_1710778717.6474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:22:50Z","timestamp":1711452170000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2816745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.3689","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}